Navigation Links
Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
Date:10/13/2008

Zero Incidence of Late Stent Thrombosis Reported in CUSTOM I, II, and III

Trials

WASHINGTON and MENLO PARK, Calif., Oct. 13 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced positive long-term follow-up data from the CUSTOM I, II and III clinical trials that reinforces the efficacy of the Custom NX(R) drug eluting stent (DES) system in treating patients with coronary artery disease. The CUSTOM clinical trials are prospective studies designed to investigate the safety and efficacy of the Custom NX DES system. The three trials have enrolled 220 patients and represent one of the most challenging patient populations -- those with long and/or multiple lesions -- ever studied in DES trials.

"We are pleased to see favorable outcome trend data continue with the CUSTOM Trials even as we look out as far as two and three years of follow-up in very complex patients," commented Pieter R. Stella, MD, Director, Cardiovascular Research, University Medical Centre Utrecht, The Netherlands, and one of the CUSTOM clinical trial investigators, who presented the data during a DES panel at the Cardiovascular Research Foundation's (CRF) twentieth annual Transcatheter Cardiovascular Therapeutics (TCT) meeting. "To date, the incidence of late stent thrombosis in all three CUSTOM trials is zero percent and this is particularly encouraging."

The results presented today include three-year follow-up data from 30 patients studied in CUSTOM I, two-year data from the 100 patients in CUSTOM II and one-year data in 90 patients enrolled in CUSTOM III. Patients enrolled in these trials presented with the smallest reference vessel diameter (RVD) ever in a DES study, and CUSTOM II featured the longest av
'/>"/>

SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Salugen Announces the U.S. Launch of GenoTrim - a DNA Customized Nutritional Solution for Weight Management
2. Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project
3. Netsmart Technologies Customer in Pennsylvania Recognized for Achieving Data Benchmarking Milestones
4. Salugen Expands U.S. Distribution and Announces a Partnership with DNA Dimensions to Bring DNA Customized Nutritional Solutions to Metro Detroit Area
5. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
6. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
7. Siemens Customers Innovate Their Clinical and Financial Workflows with Help from Soarian
8. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
9. SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations
10. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
11. Marketing and Meeting Details (M2D) Offers Customized Convention Registration and Management Tool to Clients Inside and Outside of Pharma/Biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
(Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... 18 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... authorization (CTA) for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), ... Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome, ... Healthcare Products Regulatory Agency (MHRA). BioMarin expects to initiate ...
... Inc. (OTC Bulletin Board: CSBR), a company engaged in ... data to enhance the value of oncology drugs, reports ... January 31, 2009. Full details of the Company,s ... at www.championsbiotechnology.com . Total revenues for the third ...
... forces), used by ergonomic engineers worldwide, is now more versatile and ... capacities have been doubled to accurately measure up to 300 lbs. ... ... 2009 -- HOGGAN Ergo, Ergonomic Division of HOGGAN Health Industries, ...
Cached Biology Technology:BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 3BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 4Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 5Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 6HOGGAN Ergo Announces Highly Anticipated Enhancements to the ergoFET Handheld Digital Force Gauge, Greatly Impacting the Field of Ergonomic Research and Application 2HOGGAN Ergo Announces Highly Anticipated Enhancements to the ergoFET Handheld Digital Force Gauge, Greatly Impacting the Field of Ergonomic Research and Application 3
(Date:1/22/2015)... ROBERTS, Washington , January 20, 2015 ... and tech stocks, releases video from the CES 2015 (Consumer ... consultant Apollo Robbins . Apollo shows how ... biometric smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ... "The Global Watermarking and Fingerprinting Markets" report ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides an ... fingerprinting markets. Watermarking aims to control and monitor ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 2
... Like their human hosts, bacteria need iron to survive and ... obtain iron primarily through the food they eat, bacteria have ... iron. A Syracuse University research team led by Robert ... and Sciences, discovered that some bacteria are equipped with a ...
... to achieve normal levels of blood sugar in ... levels. If this approach succeeds in humans, it ... congenital hyperinsulinism, a rare but potentially devastating genetic ... "There is currently no effective medical treatment ...
... the lowliest bacterium use molecules to communicate. Some chemicals ... still others are used to attract members of the ... have now found a rare kind of signaling molecule ... serves a dual purpose, working as both a population-control ...
Cached Biology News:Syracuse University scientists discover how some bacteria may steal iron from their human hosts 2Syracuse University scientists discover how some bacteria may steal iron from their human hosts 3Treatment corrects severe insulin imbalance in animal studies 2Treatment corrects severe insulin imbalance in animal studies 3Caltech researchers find dual-use sexual attraction and population-control chemicals in nematodes 2Caltech researchers find dual-use sexual attraction and population-control chemicals in nematodes 3
... Automatic High Sensitivity Laboratory Osmometer for both 0.2 and 2.0 mL samples for ... and record keeping. Bar code reading capability with optional scanner. RS-232 port. ... ... ...
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 alpha, CF...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: